Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CMA1 | P23946 | 3/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822203 | 0.84 | SLC6A4 (0.40) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 | |
| SCHEMBL144963 | 0.79 | IDO1 (0.41) | SLC6A4SLC6A2P2RX7IDO1PTGS2 | |
| SCHEMBL29452402 | 0.79 | HCAR1 (0.34) | TAAR1IDO1HCAR1 | |
| SCHEMBL27378816 | 0.79 | HCAR1 (0.34) | TAAR1IDO1HCAR1 | |
| SCHEMBL3166443 | 0.79 | TAAR1 (0.43) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 | |
| SCHEMBL488739 | 0.79 | PDK2 (0.41) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 | |
| SCHEMBL16701725 | 0.79 | SLC6A4 (0.39) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 | |
| SCHEMBL7230776 | 0.79 | P2RX7 (0.40) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 | |
| SCHEMBL19356887 | 0.79 | SLC6A4 (0.39) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 | |
| SCHEMBL12900215 | 0.79 | GABRA1 (0.46) | SLC6A4SLC6A2CYP2D6KCNH2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3045456-B1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9751843-B2 | Substituted uracils and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-05 | — | — | US | disclosed |
| CN-106983751-A | Two ring substituted uracils and application thereof | 拜耳医药股份有限公司 | 2017-07-28 | — | — | CN | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007065093-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | disclosed |
| CN-1764647-A | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-26 | — | — | CN | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-6939875-B2 | Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders | WARNER-LAMBERT COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | SLC6A4 651/4885SLC6A2 587/4885CYP2D6 1347/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | SLC6A4 2515/4885SLC6A2 1993/4885CYP2D6 598/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | SLC6A4 2515/4885SLC6A2 1993/4885CYP2D6 598/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | SLC6A4 4263/4885SLC6A2 4613/4885CYP2D6 1433/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | SLC6A4 3627/4885SLC6A2 4530/4885CYP2D6 2334/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | SLC6A4 2515/4885SLC6A2 1993/4885CYP2D6 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.